Patents Represented by Attorney, Agent or Law Firm Roger S. Benjamin
  • Morpholino-n-ethyl ester derivative of an indole sPLA.sub.2 inhibitor
    Patent number: 6140327
    Abstract: The compound, ((3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-(phenylmethyl)-1H-indol-4-yl)oxy)ac etic acid morpholino-N-ethyl ester, is disclosed together with its use as a highly bioavailable indole compound for inhibiting sPLA.sub.2 mediated release of fatty acids for treatment of conditions such as septic shock.
    Type: Grant
    Filed: May 12, 1999
    Date of Patent: October 31, 2000
    Assignee: Eli Lilly and Company
    Inventors: Jason Scott Sawyer, John Michael Morin, Jr., Douglas Wade Beight, Daniel Jon Sall, John Andrew Buben
  • Method for treatment of chronic bronchitis using indole compounds
    Patent number: 5972988
    Abstract: A method is disclosed for the treatment of chronic bronchitis by administering to a mammal in need thereof a therapeutically effective amount of a 1H-indole-3-glyoxylamide compound.
    Type: Grant
    Filed: March 12, 1998
    Date of Patent: October 26, 1999
    Assignee: Eli Lilly and Company
    Inventor: William Louis Macias
  • 1H-indole-3-glyoxylamide sPLA.sub.2 inhibitors
    Patent number: 5919810
    Abstract: A class of novel 1H-indole-3-glyoxylamides is disclosed together with the use of such indole compounds for inhibiting sPLA.sub.2 mediated release of fatty acids for treatment of conditions such as septic shock.
    Type: Grant
    Filed: May 14, 1997
    Date of Patent: July 6, 1999
    Assignee: Eli Lilly and Company
    Inventors: Nicholas J. Bach, Robert D. Dillard, Susan E. Draheim
  • Process for preparing 1H-indole-3-glyoxylamides
    Patent number: 5919943
    Abstract: A class of novel 1H-indole-3-glyoxylamides is disclosed together with the use of such indole compounds for inhibiting sPLA.sub.2 mediated release of fatty acids for treatment of conditions such as septic shock.
    Type: Grant
    Filed: December 16, 1997
    Date of Patent: July 6, 1999
    Assignee: Eli Lilly and Company
    Inventors: Nicholas J. Bach, Robert D. Dillard, Susan E. Draheim
  • Treatment of atherosclerosis
    Patent number: 5843938
    Abstract: The use of a compound of the formula: ##STR1## in which X is --O-- or --NH--, or a pharmaceutically-acceptable acid addition salt thereof, in the treatment of atherosclerosis.
    Type: Grant
    Filed: October 3, 1996
    Date of Patent: December 1, 1998
    Assignee: Beiersdorf-Lilly GmbH
    Inventors: Hans-Juergen Mest, Wolfgang Stenzel
  • Combinatorial process for synthesizing azetidinone analogs
    Patent number: 5759865
    Abstract: This invention relates to a combinatorial process for synthesizing a library of azetidinone peptide-like compounds. The compounds are synthesized as mixtures from a common azetidinone intermediate. The compounds are biologically active as inhibitors of the Vasopressin (V1a) receptor.
    Type: Grant
    Filed: May 3, 1995
    Date of Patent: June 2, 1998
    Assignee: Eli Lilly and Company
    Inventors: Robert F. Bruns, Michael O. Chaney, Robin D. Cooper, David C. Hunden, Gary A. Koppel, Jeffrey J. Skelton
  • 1H-indole-3-glyoxylamide sPLA.sub.2 inhibitors
    Patent number: 5733923
    Abstract: A class of novel 1H-indole-3-glyoxylamides is disclosed together with the use of such indole compounds for inhibiting sPLA.sub.2 mediated release of fatty acids for treatment of conditions such as septic shock.
    Type: Grant
    Filed: March 28, 1997
    Date of Patent: March 31, 1998
    Assignee: Eli Lilly and Company
    Inventors: Nicholas J. Bach, Robert D. Dillard, Susan E. Draheim
  • Solid-phase synthesis utilizing photochemical carbon-sulfur bond cleavage of thioethers
    Patent number: 5693720
    Abstract: A method for photochemical cleavage of carbon-sulfur bonds in conjunction with solid-phase synthesis utilizing a deoxygenated solvent and light to cleave the carbon-sulfur bond from a heterogeneous support. Also disclosed are compounds for use with said photochemical cleavage and methods of preparing them.
    Type: Grant
    Filed: June 2, 1995
    Date of Patent: December 2, 1997
    Assignee: Eli Lilly and Company
    Inventor: Irving Sucholeiki
  • 1H-indole-3-acetamide sPLA.sub.2 inhibitors
    Patent number: 5684034
    Abstract: A class of novel 1-indole-3-acetamides represented by the formula; ##STR1## is disclosed together with the use of such indole compounds for inhibiting sPLA.sub.2 mediated release of fatty acids.
    Type: Grant
    Filed: May 5, 1995
    Date of Patent: November 4, 1997
    Assignee: Eli Lilly and Company
    Inventors: Nicholas J. Bach, Robert D. Dillard, Susan E. Draheim, Robert B. Hermann, Richard W. Schevitz
  • 1H-indole-3-glyoxylamide SPLA.sub.2 inhibitors
    Patent number: 5654326
    Abstract: A class of novel 1H-indole-3-glyoxylamides is disclosed together with the use of such indole compounds for inhibiting sPLA.sub.2 mediated release of fatty acids for treatment of conditions such as septic shock.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: August 5, 1997
    Assignee: Eli Lilly and Company
    Inventors: Nicholas J. Bach, Robert D. Dillard, Susan E. Draheim
  • Oral hypoglycemic agents
    Patent number: 5641796
    Abstract: Antihyperglycemic compounds selected from the group consisting of C-substituted pentacycloazoles and N-alkyl-substituted pentacycloazoles.
    Type: Grant
    Filed: November 1, 1994
    Date of Patent: June 24, 1997
    Assignee: Eli Lilly and Company
    Inventors: Samuel J. Dominianni, Lora L. Fitch, Klaus K. Schmiegel
  • 1H-indole-1-functional sPLA.sub.2 inhibitors
    Patent number: 5641800
    Abstract: A class of novel 1H-indole-1-functional compounds is disclosed together with the use of such indole compounds for inhibiting sPLA.sub.2 mediated release of fatty acids for treatment of conditions such as septic shock. The compounds are 1H-indole-1-acetamides, 1H-indole-1-acetic acid hydrazides, and 1H-indole-1-glyoxylamides.
    Type: Grant
    Filed: April 13, 1995
    Date of Patent: June 24, 1997
    Assignee: Eli Lilly and Company
    Inventors: Nicholas J. Bach, Robert D. Dillard, Susan E. Draheim
  • Method of treating leukotriene caused diseases with N-benzyl dihydroindole LTD.sub.4 antagonists
    Patent number: 5622969
    Abstract: This invention relates to pharmaceutical N-benzyl dihydroindole compounds having the general formula: ##STR1## and their use as LTD.sub.4 antagonists.
    Type: Grant
    Filed: March 31, 1995
    Date of Patent: April 22, 1997
    Assignee: Eli Lilly and Company
    Inventor: J. Scott Sawyer
  • Glycoprotein IIb/IIIa antagonists
    Patent number: 5618843
    Abstract: This invention relates to certain bicyclic compounds having a nucleus formed of two fused six membered rings, for example, isoquinoline, isoquinolone, tetrahydronaphthalene, dihydronaphthalene, or tetralone, substituted with both basic and acidic functionality, which are useful in inhibition of platelet aggregation.
    Type: Grant
    Filed: July 8, 1994
    Date of Patent: April 8, 1997
    Assignee: Eli Lilly and Company
    Inventors: Matthew J. Fisher, Anne M. Happ, Joseph A. Jakubowski, Michael D. Kinnick, Allen D. Kline, John M. Morin, Jr., Daniel J. Sall, Marshall A. Skelton, Robert T. Vasileff
  • Beta-carboline thromboxane synthase inhibitors
    Patent number: 5604236
    Abstract: Selected acid functional beta-carboline type derivatives effective as thromboxane synthase inhibitors having the formula: ##STR1## where R.sub.1 and R.sub.2 are monovalent radicals, --(L.sub.a)-- is a linking group of 4 to 8 chain atoms, and A is an acidic group.
    Type: Grant
    Filed: May 5, 1995
    Date of Patent: February 18, 1997
    Assignee: Eli Lilly and Company
    Inventors: Joseph A. Jakubowski, Alan D. Palkowitz
  • 1H-indole-3-acetic acid hydrazide sPLA.sub.2 inhibitors
    Patent number: 5578634
    Abstract: A class of novel 1H-indole-3-acetic acid hydrazides is disclosed together with the use of such indole compounds for inhibiting sPLA.sub.2 mediated release of fatty acids (e.g., arachidonic acid) for treatment of conditions such as septic shock.
    Type: Grant
    Filed: May 12, 1995
    Date of Patent: November 26, 1996
    Assignee: Eli Lilly and Company
    Inventors: Nicholas J. Bach, Robert D. Dillard, Susan E. Draheim, Robert B. Hermann, Richard W. Schevitz
  • N-benzyl dihydroindole LTD.sub.4 antagonists
    Patent number: 5569764
    Abstract: This invention relates to pharmaceutical N-benzyl dihydroindole compounds having the general formula: ##STR1## and their use as LTD.sub.4 antagonists.
    Type: Grant
    Filed: March 31, 1995
    Date of Patent: October 29, 1996
    Assignee: Eli Lilly and Company
    Inventor: J. Scott Sawyer
  • Process for preparing benzyl-substituted rhodanine derivatives
    Patent number: 5563277
    Abstract: The instant invention provides a novel process for preparing benzyl-substituted rhodanine derivatives. The process is particularly useful for synthesizing the enantiomers of such derivatives. Also provided are novel benzyl-substituted mercaptopropanoic acids and benzyl-substituted thiazolidinones. Such compounds are useful for treating inflammatory bowel disease and, accordingly, the present invention provides a method of treating inflammatory bowel disease in mammals utilizing such novel compounds as well as pharmaceutical compositions containing same.
    Type: Grant
    Filed: December 21, 1994
    Date of Patent: October 8, 1996
    Assignee: Eli Lilly and Company
    Inventors: Marvin M. Hansen, Allen R. Harkness, Michael J. Martinelli, Vien V. Khau
  • Leukotriene B4 antagonists
    Patent number: 5552441
    Abstract: This invention provides certain 1,2,4,5 substituted benzene derivatives containing "acid" substituents derived from cyclic or heterocyclic moieties. These unique compounds are leukotriene B.sub.4 antagonists and formulations of these derivatives, and a method of using these derivatives for the treatment of conditions characterized by an excessive release of leukotrienes.
    Type: Grant
    Filed: February 14, 1994
    Date of Patent: September 3, 1996
    Assignee: Eli Lilly and Company
    Inventors: Robert D. Dillard, J. Scott Sawyer, Michael J. Sofia
  • Polyhydronorharman synthase inhibitors
    Patent number: 5550118
    Abstract: Selected acid functional polyhydronorharman type derivatives effective as thromboxane synthase inhibitors having the formula: ##STR1## where R.sub.1 and R.sub.2 are monovalent radicals, --(L.sub.a)-- is a linking group of 4 to 8 chain atoms, and A is an acidic group.
    Type: Grant
    Filed: January 31, 1994
    Date of Patent: August 27, 1996
    Assignee: Eli Lilly and Company
    Inventors: Joseph A. Jakubowski, Alan D. Palkowitz, Sandra K. Sigmund